Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Impact of somatic gene mutations on response to lenalidomide in MDS patients
EBMT 2017: Highlighting the hottest topics in the field of transplantation
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Immunotherapy for multiple myeloma: current research avenues